Dexmedetomidine Versus Propofol for Prolonged Sedation in Poly Traumatized Mechanically Ventilated Patients
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Dexmedetomidine, a central and peripheral α2-receptor agonist distinct from GABA receptor for
benzodiazepines and propofol, has been approved by the US Food and Drug Administration only
for use up to 24 h in mechanically ventilated patients. The investigators aim to compare
dexmedetomidine with propofol for sedation >24h in poly traumatized mechanically ventilated
patients.